Bernardo H.
- Country
- Spain
- Department
- Urology
Research Overview
- Phase III Randomized Trial of Docetaxel plus Apalutamide Intensification in Metastatic Hormone-Sensitive Prostate Cancer with Inadequate PSA Response
- Phase 3 Randomized, Double-blind, Placebo-controlled Study of Apalutamide and Androgen Deprivation Therapy in High-risk Localized or Locally Advanced Prostate Cancer
- Phase 3 Randomized Trial of Intravesical Erdafitinib Delivery System vs. Single-Agent Chemotherapy in FGFR+ Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Data & Insights
Has run more than one trial at 185 of 383 partner sites.
Specializations
Breast Cancer and Gynecologic Oncology
Clinical research activity is strongly centered on breast cancer, with interest in hormone receptor-positive, HER2-negative, HER2-positive, triple-negative breast cancer, and early-stage, locally advanced, and metastatic disease. The portfolio also includes ovarian cancer, endometrial cancer, cervical cancer, and related gynecological malignancies.
- Advanced breast cancer
- Triple-negative breast cancer
- HER2-positive breast cancer
- Ovarian and endometrial malignancies
Therapeutic interest extends across targeted therapy, endocrine treatment, and immuno-oncology approaches in recurrent and metastatic solid tumors.
Genitourinary Cancers
The investigator is involved in studies of prostate cancer across hormone-sensitive, castration-resistant, and metastatic settings, as well as bladder cancer and renal cell carcinoma. This includes work in urothelial carcinoma and other advanced genitourinary malignancies.
- Metastatic prostate cancer
- Non-muscle-invasive bladder cancer
- Muscle-invasive urothelial carcinoma
- Renal cell carcinoma
Research interest includes androgen receptor–directed therapy, DNA repair–targeted strategies, and treatment options for advanced urothelial disease.
Thoracic and Other Solid Tumors
There is substantial involvement in non-small cell lung cancer, small cell lung cancer, head and neck squamous cell carcinoma, pancreatic cancer, and broader advanced solid tumors. The scope also covers molecularly selected cancers, including tumors with EGFR, KRAS G12C, RET, and MET alterations.
- Non-small cell lung cancer
- Small cell lung cancer
- Head and neck squamous cell carcinoma
- Molecularly driven solid tumors
Therapeutic focus includes precision oncology, antibody-based treatments, and combination regimens for refractory and metastatic disease.
Hematologic Malignancies
Clinical trial involvement extends to multiple myeloma, acute myeloid leukemia, myelodysplastic syndromes, lymphoma, and myeloproliferative neoplasms. The research landscape includes both newly diagnosed and relapsed or refractory blood cancers.
- Multiple myeloma
- Acute myeloid leukemia
- Myelodysplastic syndromes
- Lymphoma
Interest is directed toward novel immunotherapies, targeted agents, and approaches for treatment-resistant hematologic disease.
Cardiometabolic, Hepatic, and Respiratory Disease
The investigator also participates in studies of atherosclerotic cardiovascular disease, heart failure, atrial fibrillation, obesity, type 2 diabetes, non-alcoholic steatohepatitis, and chronic liver disease. Additional activity includes chronic obstructive pulmonary disease, asthma, and idiopathic pulmonary fibrosis.
- Cardiovascular disease
- Metabolic disease
- Non-alcoholic steatohepatitis
- Chronic obstructive pulmonary disease
Therapeutic emphasis includes cardiovascular risk reduction, metabolic disease management, and treatment options for fibrotic and inflammatory organ disease.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.